$CADL News

Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate Cancer

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript

Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual Meeting

Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate

Candel Therapeutics To Hold Conference Call On May 15 To Discuss Extended Follow-Up Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec In Participants With Intermediate- To High-Risk Localized Prostate Cancer

Candel Therapeutics Enters Product Commercialization Agreement With EVERSANA To Support Potential U.S. Launch Of Localized Prostate Cancer Treatment Aglatimagene Besadenovec

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics shares are trading higher after Cantor Fitzgerald initiated its coverage on the stock with an Overweight rating.

Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

Citigroup Maintains Buy on Candel Therapeutics, Raises Price Target to $26

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Non-Small Cell Lung Cancer Treatment

Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $22

Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate

Candel Therapeutics To Present New Data From Phase 3 Clinical Trial Of Aglatimagene Besadenovec In Patients With Intermediate- To High-Risk Localized Prostate Cancer At AUA 2026 Annual Meeting Plenary Program

12 Health Care Stocks Moving In Friday's Intraday Session

Candel Therapeutics shares are trading lower after the company announced the pricing of its $100 million offering of 18,348,624 shares at $5.45 per share.

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Is Candel Therapeutics Stock Falling Friday?